News & Announcements

Weil Advises Johnson & Johnson Innovation – JJDC, Inc. on its Secondary Offering of Common Stock of Achillion Pharmaceuticals, Inc.

A Weil team advised Johnson & Johnson’s subsidiary, Johnson & Johnson Innovation – JJDC, Inc., in connection with its sale of 18,367,346 shares of common stock of Achillion Pharmaceuticals, Inc. The joint book-running managers for the offering were Goldman Sachs & Co. LLC and Leerink Partners LLC. The transaction closed on November 20, 2017.

The New York-based Weil team was led by Capital Markets partner Frank Adams, and included Capital Markets associates Janeane Ferrari and Sarah Curry.